BRUSSELS, July 3 (Reuters) – The European Commission said on Friday it had given conditional approval for the use of antiviral remdesivir in severe COVID-19 patients following an accelerated review process, making it the region’s first authorised therapy to treat the virus.
The move comes just a week after the European Medicines Agency (EMA) gave its go-ahead for the drug, produced by Gilead Sciences, to be used in adults and adolescents from 12 years of age who are also suffering from pneumonia and require oxygen support.
It also comes just days after the company allocated nearly all of its supply of remdesivir to the United States over the next three months, stirring concerns about availability elsewhere.
“We will leave no stone unturned in our efforts to secure efficient treatments or vaccine against the coronavirus,” said Stella Kyriakides, EU Commissioner for Health and Food Safety, in a statement.
The Commission said on Wednesday it was in negotiations with Gilead to obtain doses of remdesivir for the 27 European Union countries.
Remdesivir is in high demand after the intravenously-administered medicine helped to shorten hospital recovery times in a clinical trial.
It is believed to be most effective in treating COVID-19 patients earlier in the course of disease than other therapies like the steroid dexamethasone.
Still, because remdesivir is given intravenously over at least a five-day period it is generally being used on patients sick enough to require hospitalisation.
The EU’s green light broadens the use of remdesivir around the world – the United States has cleared it for emergency use and it is also approved as a COVID-19 therapy in Japan, Taiwan, India, Singapore and the United Arab Emirates, Gilead said on Friday.
A conditional marketing authorisation is one of the EU regulatory mechanisms created to facilitate early access to medicines that fulfil an unmet medical need, including those for emergency situations in response to public health threats such as the current pandemic, the Commission said.
The approval is valid for one year in the bloc and can be extended or converted into an unconditional marketing authorisation if all necessary data are available on its efficacy and side effects.
The agency reviews data as they become available on a rolling basis, while development is still ongoing. The EMA’s rolling review began at the end of April.
(Reporting by Philip Blenkinsop; Writing by Josephine Mason; Editing by Jane Merriman and Elaine Hardcastle)
Our Privacy Commitment
TV5 Network Inc. values and respects your right to privacy. We are committed to safeguarding your personal data in compliance with Republic Act No. 10173 or the Data Privacy Act of 2012 and its Implementing Rules and Regulations.
Why do we collect your personal information (as applicable)?
We collect and maintain basic information about you as users of TV5 sites for the following purposes:
Where do we get your personal information?
There are several ways we collect your personal information.
Information that you personally provided.
Most of the personal information we have are those that you have provided us when you:
Information we collect during your engagement with us
We also collect information as you use our products and services, like:
Information we collect from other sources
We also collect your personal information through other activities such as our market research initiatives, when you visit and use our websites and mobile apps, and from our subsidiaries, affiliates, and third-party business partners to whom you have given consent to share your information to us.
When do we disclose personal information?
There are circumstances when we are required to share some of the information you have provided us. In these cases, we ensure that your personal information will be disclosed on a confidential manner, through secure channels that is in compliance with the Data Privacy Act and other privacy laws.
In some instances, we may be required to disclose your personal information to our agents, subsidiaries, affiliates, business partners and other third-party agencies and service providers as part of our regular business operations and for the provision of our programs and services. This means we might share your information with:
How we protect your personal information
We also put in effect the following safeguards:
TV5 will not collect, use, or disclose your personal information for any purpose other than those identified in this Commitment, your Service Agreement or our Terms of Service, and any other purpose that you may have given your consent for.
For greater clarity, unless you provide specific consent, we shall not:
What are your choices?
You are given certain rights in relation to your personal data under the Data Privacy Act. We would like to ensure that we have your consent to continue to collect, use, and disclose your personal information for the purposes that we have identified. We want you to know that you do have choices and can object or withdraw your consent and/or edit your consent preferences at any time.
If you wish to have access to your personal information in our records; or you think that such personal information we have of you is incomplete, not up-to-date, or otherwise inaccurate, you may get in touch with our Data Privacy Officer through the contact details provided below. In some instances, we may request for supporting documents or proof before we effect any requested changes to your personal information.
Data Protection Officer
TV5 Network Inc.
Reliance corner Sheridan Streets
What happens when there are changes in our Policy?
You will always be provided notice if these changes are significant and, if we are required by law, we will ensure to obtain your updated consent.